NCT02944955尚未招募2 期
A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 52
- 主要终点
- Part I: Recommended dose level (RDL) of BLEX 404 Oral Liquid
研究概览
简要总结
This is a clinical trial to determine the safety, recommended dose level (RDL), and infection control of BLEX 404 Oral Liquid in combination with azacitidine in patients with International Prognostic Scoring System (IPSS) intermediate-1 (int-1), intermediate-2 (int-2) or high-risk myelodysplastic syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 20 or older, able to sign informed consent, understand and comply with protocol requirements and instructions.
- •Body weight between 30 to 120 kg
- •International Prognostic Scoring System (IPSS) intermediate-1 (int-1), intermediate-2 (int-2) or high-risk myelodysplastic syndrome (MDS) by World Health Organization (WHO) or Chronic Myelomonocytic Leukemia (CMML) patients.
- •Not previously treated with MDS and CMML therapy and require treatment with azacitidine* for the first time at 75 mg/m2 subcutaneously or intravenously, daily for 7 days (7 nonconsecutive day of 6-1-1 or 5-2-2 treatment schedule is acceptable in which the drug is administered Monday-Saturday and then Monday of the following week for a 6-1-1 schedule, and in which the drug is administered Monday-Friday and then Monday-Tuesday of the following week for 5-2-2 schedule) per cycle. Treatment of the study drug, BLEX 404 Oral Liquid will begin at the same time receiving the first dose of azacitidine in this study.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0-
- •Adequate baseline organ function defined by the criteria below: total bilirubin ≤ 1.5x the upper limit of normal (ULN) except for Gilbert's syndrome or indirect hyperbilirubinemia due to hemolysis; ALT ≤ 2.5x ULN; AST ≤ 2.5x ULN; creatinine clearance ≥ 60 mL/min/1.73 m
- •Women must be either of non-child bearing potential, or women with child-bearing potential and men with reproductive potential and a female partner of childbearing potential must either have had a prior vasectomy or agree to use effective contraception from time of Screening Visit until the Follow-Up Visit.
排除标准
- •Historical allergic events caused by mushroom.
- •Previous treatment with hypomethylating agent or known immediate or delayed hypersensitivity reaction to drugs chemically related to azacitidine that contraindicates the subjects' participation.
- •Patients with active infections or require treatments with immunosuppressive drugs at screening visit. However, patients require ongoing treatments with corticosteroids may be recruited.
- •Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of BLEX 404 Oral Liquid.
- •Any serious and/or unstable pre-existing medical condition (including any advanced malignancy other than the disease under study), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance with the study procedures.
- •Any clinically significant pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal or genitourinary disease unrelated to underlying hematologic disorder.
- •Active and uncontrolled infections of the following: hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV) infection. However, HBV and HCV carriers with viral load test of "not detected" or "negative" results may be recruited in this study.
- •Lactating female and women with a positive serum or urine pregnancy test at screening assessments.
- •(For Part II Interventional Study subjects only) No indication, in the opinion of the treating physician, for antibiotic prophylaxis within 2 weeks prior to study treatment.
研究组 & 干预措施
BLEX 404 Oral Liquid
Experimental
Part I:
Part I-1: Low Dose BLEX 404 Oral Liquid (3 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.
Part I-2: High Dose BLEX 404 Oral Liquid (4.5 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.
Part II:
Recommended Dose Level (RDL) of BLEX 404 Oral Liquid will be determined by results from Part I.
BLEX 404 Oral Liquid at RDL is administered in combination with 6 cycles of azacitidine.
干预措施: BLEX 404 Oral Liquid (Drug)
结局指标
主要结局
Part I: Recommended dose level (RDL) of BLEX 404 Oral Liquid
时间窗: 8 weeks (2 cycles of azacitidine)
RDL is defined by BLEX 404 Oral Liquid-related prohibited toxicity in subjects undergoing 2 cycles of azacitidine treatment. When one of the stopping criteria is met during the study treatment period, RDL will be set at the lower dose level.
Part II: Incidence of infections
时间窗: 24 weeks (6 cycles of azacitidine)
Number of subjects experience infection events and inpatient hospitalization due to infections.
次要结局
- Part I: (B) Treatments and duration of each infections(8 weeks (2 cycles of azacitidine))
- Part I: (C) Complete remission (CR) or partial remission (PR) of bone marrow, peripheral blood, cytogenetic response (defined by 2006 IWG Criteria)(8 weeks (2 cycles of azacitidine))
- Part I: (D) Hematological improvement of erythroid (hemoglobin and RBC-transfusion independence), neutrophil (Absolute Neutrophil Count), and platelet (platelet count) response (defined by 2006 IWG Criteria)(8 weeks (2 cycles of azacitidine))
- Part I: (A) Number of subjects experience infections events and inpatient hospitalization due to infections(8 weeks (2 cycles of azacitidine))
- Part I: (E) Frequency and requirement of red blood cell transfusion (defined by 2006 IWG Criteria)(8 weeks (2 cycles of azacitidine))
- Part I: (F) Disease Progression (defined by 2006 IWG Criteria)(8 weeks (2 cycles of azacitidine))
- Part II: (A) Time-to-first infection(24 weeks (6 cycles of azacitidine))
- Part II: (B) Duration (days) of each infection event(24 weeks (6 cycles of azacitidine))
- Part II: (C) Number of infections requiring supportive care or antimicrobial agents(24 weeks (6 cycles of azacitidine))
- Part II: (D) Duration (days) of treatments for infections(24 weeks (6 cycles of azacitidine))
- Part II: (E) Complete remission (CR) or partial remission (PR) of bone marrow, peripheral blood, cytogenetic response (defined by 2006 IWG Criteria)(24 weeks (6 cycles of azacitidine))
- Part II: (F) Hematological improvement of erythroid (hemoglobin and RBC-transfusion independence), neutrophil (Absolute Neutrophil Count), and platelet (platelet count) response (defined by 2006 IWG Criteria)(24 weeks (6 cycles of azacitidine))
- Part II: (G) Frequency and requirement of red blood cell transfusion (defined by 2006 IWG Criteria)(24 weeks (6 cycles of azacitidine))
- Part II: (H) Disease Progression (defined by 2006 IWG Criteria)(24 weeks (6 cycles of azacitidine))
- Part II: (I) Six-month overall survival rate (defined by 2006 IWG Criteria)(24 weeks (6 cycles of azacitidine))
- Part II: (J) Six-month progression-free survival (defined by 2006 IWG Criteria)(24 weeks (6 cycles of azacitidine))
- Part II: (K) Immune Response(24 weeks (6 cycles of azacitidine))
研究者
相似试验
终止
1 期
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy SubjectsViral InfectionNCT02696291Emergent BioSolutions7
招募中
1 期
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological MalignanciesGynecological Malignant TumorSolid TumorNCT05803018Sichuan Baili Pharmaceutical Co., Ltd.38
终止
4 期
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe DiseasePompe DiseaseNCT01526785Genzyme, a Sanofi Company113
招募中
1 期
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine CarcinomaNCT06157827Nanjing Leads Biolabs Co.,Ltd178
已完成
2 期
Clinical Trial in Subjects With Mild to Moderate Acne VulgarisAcne VulgarisNCT02832063AOBiome LLC372